Description
Triacetyl resveratrol is a resveratrol prodrug designed to improve bioavailability of the parent compound. Triacetyl resveratrol displays a wide variety of anticancer and chemopreventive activities. In an in vitro model of prostate cancer, this compound activated p53, increased levels of p21 and p53R2, and decreased prostate-specific antigen expression, inhibiting cell cycle progression at the G1/S phase in p53-mutated cells and at the SG2/M phase in p53 null cells. In breast cancer cells, triacetyl resveratrol interacted with integrin αvβ3 and induced phosphorylation of ERK and p38, regulating gene expression and proliferation.